The artificial intelligence drug developer has closed a $225m round led by SoftBank Vision Fund 2, which has offered a further $300m in funding.
Telecommunications and internet group SoftBank’s Vision Fund 2 led a $225m series D round for UK-based, artificial intelligence-equipped drug developer Exscientia yesterday. The round also featured pharmaceutical firms Novo and Bristol-Myers Squibb in addition to Pivotal BioVenture Partners, the life sciences venture capital fund formed by property developer Nan Fung’s Life Sciences subsidiary. The Abu…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.